Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5428]

4 years of RESONATE data for CLL patients treated with ibrutinib

Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona...

4 years of RESONATE data for CLL patients treated with ibrutinib ( Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )

Latest maintenance strategies in multiple myeloma

Prof Guillermo Ruiz-Arguelles and Prof McCarthy

Latest maintenance strategies in multiple myeloma ( Prof Guillermo Ruiz-Arguelles and Prof McCarthy )

Front-line combinations in multiple myeloma: Highlights from EHA 2017

Prof Joy Ho and Prof Je-Jung Lee

Front-line combinations in multiple myeloma: Highlights from EHA 2017 ( Prof Joy Ho and Prof Je-Jung Lee )

Denosumab or zoledronic acid for bone disease in multiple myeloma

Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece

Denosumab or zoledronic acid for bone disease in multiple myeloma ( Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece )

Hemcare - multiple myeloma learning programme

Erik Aerts - President of HNHCP, Winterthur, Switzerland

Hemcare - multiple myeloma learning programme ( Erik Aerts - President of HNHCP, Winterthur, Switzerland )

Extended followup indicates daratumumab with bortezomib and dexamethasone for...

Prof Katja Weisel - University of Tübingen, Tübingen, Germany

Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )

Enasidenib in mIDH relapsed and refractory AML

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA

$Enasidenib in mIDH relapsed and refractory AML ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )$

Delayed infection exposure as a trigger for childhood ALL

Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany

Delayed infection exposure as a trigger for childhood ALL ( Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany )

Triplet therapy for all comers in the CLL-BAG trial

Dr Paula Cramer – University of Cologne, Cologne, Germany

Triplet therapy for all comers in the CLL-BAG trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )

The role of patient advocates in trial design, participation

Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy

The role of patient advocates in trial design, participation ( Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy )

Disruption of BAFF-BCR crosstalk in CLL

Dr Alexey Danilov - Knight Cancer Institute, Portland, USA

Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )

Phase Ib/II study of nivolumab in combination with azacytidine in patients with...

Prof Naval Daver - MD Anderson Cancer Center, Houston, USA

Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML ( Prof Naval Daver - MD Anderson Cancer Center, Houston, USA )

More from ecancer